Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination
- 1 December 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (12) , 2348-2353
- https://doi.org/10.1128/aac.34.12.2348
Abstract
The in vivo efficacy of daptomycin, a new cell wall-active anti-gram-positive-bacterial agent, was compared to those of cloxacillin and vancomycin in a rat model of Staphylococcus aureus endocarditis. Both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains were used. When therapy was initiated early (8 h) after infection, at the time when valvular bacterial counts were relatively low (approximately 10(6) CFU/g of vegetation), 3 days of therapy was found to be effective against the MSSA strains whatever the antibiotic regimen. In contrast, when the onset of therapy was delayed up to 15 h after infection, so that higher bacterial counts could develop on the valves (approximately 10(9) CFU/g of vegetation), a longer period of treatment (6 days) was required to cure infection. Under these conditions after 3 days of therapy, daptomycin was more effective than cloxacillin and vancomycin against the MSSA strains. Similarly, daptomycin showed a greater activity than vancomycin against the MRSA strain after 3 days of treatment, but after 6 days both antibiotics were equally effective. Decreasing doses of daptomycin showed decreasing activity: 10 mg/kg of body weight every 12 h (q12h) was better than 5 mg/kg q12h, whereas 5 mg/kg q24h (providing drug levels in blood detectable only during the first 12 h) failed to cure infection. In vitro, daptomycin was highly bactericidal at high concentrations (25 and 60 micrograms/ml, corresponding to peak levels in serum after doses of 5 and 10 mg/kg, respectively) and bacteriostatic at lower concentrations (0.5 to 2.5 micrograms/ml, corresponding to trough levels in serum). In conclusion, against low-bacterial-count S. aureus endocarditis, daptomycin showed an efficacy similar to those of vancomycin and cloxacillin. Against high-bacterial-count S. aureus endocarditis, daptomycin showed a higher bactericidal activity than cloxacillin (against the MSSA strains) and vancomycin (against both the MSSA and MRSA strains).This publication has 12 references indexed in Scilit:
- Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbitsAntimicrobial Agents and Chemotherapy, 1989
- Daptomycin (LY146032) treatment of experimental enterococcal endocarditisAntimicrobial Agents and Chemotherapy, 1988
- Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1988
- LY146032 compared with penicillin G in experimental aortic valve endocarditis caused by group G streptococciAntimicrobial Agents and Chemotherapy, 1988
- Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studiesAntimicrobial Agents and Chemotherapy, 1987
- Activity of LY146032 in vitro and in experimental enterococcal pyelonephritisAntimicrobial Agents and Chemotherapy, 1987
- In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocciAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibioticAntimicrobial Agents and Chemotherapy, 1986
- Discrepancies between MBC and actual killing of viridans group streptococci by cell-wall-active antibioticsAntimicrobial Agents and Chemotherapy, 1986
- Influence of the developmental state of valvular lesions on the antimicrobial activity of cefotaxime in experimental enterococcal infectionsAntimicrobial Agents and Chemotherapy, 1985